{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","since":null,"total":50,"cursor":0,"limit":50,"next_cursor":null,"events":[{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-11-07","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Full Year 2025 ...","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-archive/3279553/11666/en/vivoryon-therapeutics-n-v-reports-full-year-2025-financial-results-and-provides-business-update.html/timezone/Romance%20Standard%20Time?dateformat=dd+MMMM+yyyy","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"K246Rs5N40X6jQHde33SChlPl1mLM2sGMHOuawpuvsjaygusk-ccOXn1-mZVajBtKTTf704Ke8xetpFJB7uhCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-11-05","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. Reports Q3 2026 Financial","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/11/05/3396030/0/en/vivoryon-therapeutics-n-v-reports-q3-2026-financial-results-and-provides-business-update.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"i25QuCQQeO76-YTaJ3qlgJ9k-gqR5aVTvTFnVefh8II-KKhPvAqBkizh3Z2J57ZM7ypQ2H8XAV9wtzFoM9jaAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-11-05","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2611-00289","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"6AeEVlgYh8PwFVJRBwqVskOFKKCB50ClNYSMVS9ng3JrGnYi8BNMwpTaD8RyJQaTxEaWP89U1X0km4vKRFW-Bg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-11-05","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2609-00903","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: ForFarmers N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"wl1-p0CITOMx9aKELnlM1VsTUc6TepWcN5z6Gsmv-EFy0ZirxpU7KdeYccKNxthDx4sOeTGeeJY-LCIAJSXGCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-11-04","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. to Report Q3 2026 Financial ...","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-archive/3392040/11666/en/vivoryon-therapeutics-n-v-to-report-q3-2026-financial-results-on-november-5-2026.html/timezone/Romance%20Standard%20Time","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"E9j3BG86YmengEA8OfztzmX2KCa-SpMCo4yeZktyWUljboJtquBx_DHiqdbdw8LCK0WbIExKBE62qoqPKKlGAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-10-30","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. to Report Q3 2026 Financial","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/10/30/3392040/0/en/vivoryon-therapeutics-n-v-to-report-q3-2026-financial-results-on-november-5-2026.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"vfXkXWzgIZ39ji3RW3NySiMOoCihNgnsyHkwmrw8UUD2i7aCvUMzXuLFHuqeHchmmGeo5lZeTLEVqFYlGBmXDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-10-30","event_type":"results","title":"Vivoryon Therapeutics N.V. to Report Q3 2026 Financial Results on November 5, 2026","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2610-01634","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"1s0cIZzEdqgcyL70-apyVr-1nxphtVBaSJ4IfeKjKXCOGtq86hdahV3q39CUEU03vIUFJowySJiy7FJeGC5tCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-10-28","event_type":"newswire_release","title":"TENX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Tenax Therapeutics, Inc. - PR Newswire","wire":"PR Newswire","source":"PR Newswire","url":"https://www.prnewswire.com/news-releases/tenx-stockholder-notice-shareholder-rights-law-firm-robbins-llp-reminds-investors-of-the-class-action-lawsuit-against-tenax-therapeutics-inc-302921469.html","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"xFQA_rvdkPLBNvIhpJLL2iY-h5-DjTGCA6useWPmW0BzezwUWH0KkM5mcDngy8jSdgHZ0DiAsJQVUF2ZA0oIAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-10-20","event_type":"newswire_release","title":"Unicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire","wire":"PR Newswire","source":"PR Newswire","url":"https://www.prnewswire.com/news-releases/unicycive-deadline-uncy-investors-have-opportunity-to-lead-unicycive-therapeutics-inc-securities-fraud-lawsuit-302913660.html","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"TEm3KcHHjz8EmJ_v32z1Sv80HYhXNDVA2iurl5ufpLCpJvq02L7xx4fjN6ED9Os0AgAE816ovVfWTNsZas8ADw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-09-29","event_type":"agm_egm","title":"Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual General Meeting","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2609-01647","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"TVeH9qmQLavYT7CC0SjbTgVafdy9RuyB35t6HY6P3FdOjWFHNCm_SRm6FP0VDcsPI4D4AQFjKYWgZtArv-QGCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-09-29","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. Reports Outcome of 2026 Annual","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/09/29/3371171/0/en/vivoryon-therapeutics-n-v-reports-outcome-of-2026-annual-general-meeting.html","read_by":"Tavily search (wire domains) + published_date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"hZh1veEs4v2B94yIR08HeczutUPOCvZzdRx7vIrNAsy0fQa21Z82tHgbQGZ8hzpYZ2phoyacUdSRfPF4GuDwDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-09-09","event_type":"newswire_release","title":"CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire","wire":"PR Newswire","source":"PR Newswire","url":"https://www.prnewswire.com/news-releases/capr-deadline-capr-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-capricor-therapeutics-inc-securities-fraud-lawsuit-302873126.html","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"nZVbbRaUH2HY-DXjMkuxiPv6JXZuJQmdh-yyXbfnp4rxwR8eFZ6fEqS-iPJFoWmiZEcn5L-hIWB7lLmeHwIwCQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-09-06","event_type":"newswire_release","title":"AARD Investors Have Opportunity to Lead Aardvark Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire","wire":"PR Newswire","source":"PR Newswire","url":"https://www.prnewswire.com/news-releases/aard-investors-have-opportunity-to-lead-aardvark-therapeutics-inc-securities-fraud-lawsuit-302870529.html","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Wq8DSsC6P9Vmlc5N9_yquQ3sWBK_F-cPSlAvffr9oQOYNrgzTgUwvV1xZAJYP5K5G8fRUY3j8JMbGPUucIZuCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-08-18","event_type":"agm_egm","title":"Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2608-00883","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"S-xFixbhCIkRdFyik9RzPHSs8fCG03jmFid4kPFxmY7Ke7_BlWz5RRYHh5cibnxCJOfBNiH0MgD_jYHYKv4hCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-08-06","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2608-00245","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"e3sRhHWG-KzBgS6Z8tS73RWyxv9zH1bMGxzFUh9DzdOAEAGdYaGVJ2auWFalgoGrl8-uuzH0q-q0Jai8hwbzCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-08-06","event_type":"results","title":"2026","category":"financial reporting","language":"nl","wire":"AFM","source":"AFM register — financial reporting","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/financiele-verslaggeving/details?id=A2510-03969","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: financial reporting; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"XjL6Uf2q4NZwmL-FjUv5A5rlqAmnOsRT_RqfgjfnaNDRD7-gHiOOGH0x27I5ey6hB7eM5Lj3jlgaCrYci6_bCA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-07-22","event_type":"results","title":"Vivoryon Therapeutics N.V. to Report H1 2026 Financial Results and Business Updates on August 6, 2026; Annual General Meeting Planned for End of September 2026","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2607-01331","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"RVpODHcW0pFILJSt_tROrxV9wETl6XTvcGzUjRfr6SLws0CkbMMPDTpNrUnVQd5FD4XyvaszfmDy2v7aib_2Dg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-06-11","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Q1 2026 Financial Results and Provides Business Update","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2606-00607","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"tDJHP3Z3ymnUuibAsZDa4u9ljfYyGVgt1IJOEiXl9fbNmm83Uye8kkGHhtvcYFiFkFdgswI9KMfd75173phZAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-06-08","event_type":"results","title":"Vivoryon Therapeutics N.V. to Report Q1 2026 Financial Results on June 11, 2026","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2606-00391","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"e-HFEZRXr67t5K6RMVDEs-dTbV8o4Q4wYu-ZNCjOspD5pB4FCMe1_AW0wVg5iEvJUe8G_gxSq3YSwi3sKnMhCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-23","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2604-01662","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"p96ZWgOjIyiOEJca0eDMFCCN70ASzJwqb16FC_DCdOBaICKgIIVoJA9WeEbIJPdSgqgWy8aWvp61O3z9MhpMAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-23","event_type":"results","title":"2025","category":"financial reporting","language":"nl","wire":"AFM","source":"AFM register — financial reporting","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/financiele-verslaggeving/details?id=A2510-03687","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: financial reporting; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"cr7v2FyFiJQfsfymQ24gJjO7XXlvJftxzsh6ns_PAVNXI7ttYEMtJP1PfItFU_29Ofb_Q0xOBX7Jfjnd0AYKBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-23","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results  and Provides Business Update","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/23/3279553/0/en/vivoryon-therapeutics-n-v-reports-full-year-2025-financial-results-and-provides-business-update.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"KosPhn0XGFf_4OOIeoNZ1FgPMtXVCSJ_OWvwrHui5H_1UYLPMPmZk7jq0P4wdVZm_VL4kVQM4J3rb6PdrhEUCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-23","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/de/news-release/2026/04/23/3279553/0/en/vivoryon-therapeutics-n-v-reports-full-year-2025-financial-results-and-provides-business-update.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"WomRXndKMfcdmYG84KJbA0NDQjLoDFouCNYpFjvptTdVB6ByY9gvRFULuPlk_pro6qRe1R4CX1HOQ0nRwhSIAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-17","event_type":"directors_dealings","title":"M. Schaeffer","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=192625","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Jq84Rr5YBb_3lCqQDoBDeFRk2evokCQkDHvsYm_nznAXk8YVRIpINbYRXeXnfOXZgrIA7psAbVwlOcyBC52FAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-17","event_type":"directors_dealings","title":"J. Neugebauer","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=192632","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"F2JAPvNYRGJzyztz5ULbLG6bohy2qVQjnOyI4nTDxeR3htsygKAaHC2kkc_4DuUa6iaarYpuciNh3RL0XQDtAw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-17","event_type":"directors_dealings","title":"F. Weber","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=192721","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"yp2zUtVh-wIalNHxoGqPCa6hVbKMf0UFQ0OOiP9IYqEYty03zOTJCIlYR4m5enfzLkb4GcnFhQgov-TV0WgJAQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-15","event_type":"results","title":"Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2604-00964","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"uhj_BLBf1y5dyZwu9B0AoNOMc8K5wxAZ8_BHYw3wmg1W6kXGCOG36uHEduHf8JODG0vMCVgXJhKiCHCeqh3fDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-15","event_type":"results","title":"Vivoryon Therapeutics N.V. to Report Full Year 2025","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/04/15/3274111/0/en/Vivoryon-Therapeutics-N-V-to-Report-Full-Year-2025-Financial-Results-and-Business-Updates-on-April-23-2026.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"jMzJZ60sgSQcZqOWfPq6QGN2ekkYjOgT_FnxWg1MKvioD6VlRRPhdXA2nl9BYoVKNft2uxyLKSrTQ4Lp2dQXAA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-04-09","event_type":"ad_hoc","title":"Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2604-00594","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"-vwL638e4XoXZn1NibRWiMwemmO0c_tXXTaY4x7fRx6B1npIP80R8b7dGK1ivFkPu1meRp25SScT--_czv7eBQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-03-28","event_type":"ad_hoc","title":"Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2603-01982","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"YGbkKHcNzFB6vyf_MfpjqFnA_eyePRXhEXQAssaRxPWhXuOI_tJbxO4gjmYyUae7c_OpzOcHenjoxbrxpChjDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-03-28","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. Provides Update on Growing Body","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/fr/news-release/2026/03/28/3264170/0/en/Vivoryon-Therapeutics-N-V-Provides-Update-on-Growing-Body-of-Evidence-Validating-Glutaminyl-Cyclases-as-Promising-Targets-in-DKD-at-World-Congress-of-Nephrology.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"wFKZYYSzDDoLEZnmT8lqA4xXwKWg35GXhamwxTY50uBtnKAw_4s-W3Ug18zQw-gi-gyTrbBbAwtYElKnr1i5BQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-03-28","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. Provides Update on Growing Body","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/03/28/3264170/0/en/Vivoryon-Therapeutics-N-V-Provides-Update-on-Growing-Body-of-Evidence-Validating-Glutaminyl-Cyclases-as-Promising-Targets-in-DKD-at-World-Congress-of-Nephrology.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Go5HA2Eqx7CnbqCpboD_w0zjHMOfEj8paJSwuakYIjKAkf7pUrtioeLNbxiddcz7Cj6jd3_AhgJZcD0iq86WCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-03-28","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. Provides Update on Growing Body","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/de/news-release/2026/03/28/3264170/0/en/Vivoryon-Therapeutics-N-V-Provides-Update-on-Growing-Body-of-Evidence-Validating-Glutaminyl-Cyclases-as-Promising-Targets-in-DKD-at-World-Congress-of-Nephrology.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"kVjE3eBiQVudjK_vn-07AW5lSYEAx8FxU07Cxpz2V6e3V1nXPIBKWEolBNaSG7RZDD_Lc9rXj94Pu1x8nYfdBA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-02-27","event_type":"newswire_release","title":"Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - GlobeNewswire","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/02/27/3246256/0/en/Portnoy-Law-Firm-Announces-Class-Action-on-Behalf-of-Corcept-Therapeutics-Incorporated-Investors.html","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"wNiqEE5_SuWL0a7YJ-ZsJ7OCiP_cE00vgdmoAdBCxWks5eX2so6gHmZI0U0H0ZStBmLrjbBIqSeRWQgRmyQKCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-01-18","event_type":"newswire_release","title":"ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Vistagen Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTGN - TMX Newsfile","wire":"Newsfile","source":"Newsfile","url":"https://www.newsfilecorp.com/release/280699/ROSEN-NATIONAL-INVESTOR-COUNSEL-Encourages-Vistagen-Therapeutics-Inc.-Investors-to-Secure-Counsel-Before-Important-Deadline-in-Securities-Class-Action-VTGN","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"JwNbhWMCbgUTubzWPhf6pwaNjO_2YWG1hEu1zDU2bx6CvFt8-VlEeRKgduOU7rYW_3zua99PimUX2lc1sqsqCQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-01-07","event_type":"ad_hoc","title":"Vivoryon Therapeutics N.V. to Attend and Present in Upcoming Conferences","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2601-00335","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"AQpo-U1dRv5cbX1SX18KTZGAE5YOIlaon7d44MyYrprlfWGs38AsHN1iTFsuGmTrLH8qjTjwYxoro-FVDHFfBw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2026-01-07","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. to Attend and Present in","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2026/01/07/3214259/0/en/Vivoryon-Therapeutics-N-V-to-Attend-and-Present-in-Upcoming-Conferences.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"HiQdEM93I4p-bQeV2KOurO7Pop8a7Cohzhj5guIXjkUeviojRWs5uMILHuHnEJ9nOZKot6KSbBU5XijCpwVcAg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-12-10","event_type":"directors_dealings","title":"F. Weber","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=184722","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"jG5-GRrzwzdTHVdgDNRsL93a0Vv-NQxzY6oZ6T62E1VTHzeqaUwVU3JIF8hw3fuQ2hR6zVzS_64G6ag_kiDlDg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-12-08","event_type":"directors_dealings","title":"E. Platzer","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=184550","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"OxTML03w0cn26fT9C619N4zmsQa0d0ZcXAJLrL9ranZT3aSrr7_L4HuuHSiL1UuImaHshC3L4ZQA9-CJqKpLBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-12-04","event_type":"results","title":"Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2512-00364","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"jIdTx6__-snUWe5YWU6lA6B_Vp_fo6_WLqLHMwPBapbd2EpgrBmR6hBWZTjWJKuQC2vXavgZYGR1Sm4LiogfDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-11-25","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. to Report Q3 2025 Financial","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2025/11/25/3194014/0/en/Vivoryon-Therapeutics-N-V-to-Report-Q3-2025-Financial-Results-and-Operational-Progress-on-December-4-2025.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"gwUjSO25eqCD4C_ouvdr645oQGFlx9wgE8HkpwiMtTl5sXvkO_RmdbQYbxs9ZR6tZ1FgbEqxl10RX52hfkmUCQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-11-25","event_type":"results","title":"Vivoryon Therapeutics N.V. to Report Q3 2025 Financial Results and Operational Progress on December 4, 2025","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2511-01329","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"5ghbpi0tKZ0XN_6yfYTAY2cTglhf12Ry599aSMCIU7G9gcpelmayw6YPlLIdJgwaelo3C1OkXggu5Yce9dxcCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-11-06","event_type":"ad_hoc","title":"Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2511-00372","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Z4abwBBDF888uMzShksbbY2q6EZ6el7Hl0o7J_M9kuOO8mPdbsJvBHnXUsP_oACe7XugOukhquK4WJlmDe6uBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-11-06","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2025/11/06/3182889/0/en/Vivoryon-Therapeutics-N-V-Presents-Phase-2-Kidney-Function-and-Biomarker-Data-at-the-American-Society-of-Nephrology-Kidney-Week-2025.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"Bj2JSCPxcQLCztwOkcleA60mUWJylXgjPNSCL0DkdxC8cAkYumE_huHM_wFYKvaAPc5aZZpIt1I2xYDEduA-AA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-11-03","event_type":"ad_hoc","title":"Vivoryon Therapeutics N.V. to Present at Upcoming Conferences","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2511-00016","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"jmLHnbnKoRLqzTy055qs4TeM7TDM5sH3YV5_fDQrNW6x4Jlu_eJOPvffZbFJ3gkZLSWnlI0PnFuIW3AyiLrNCQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-11-03","event_type":"newswire_release","title":"Vivoryon Therapeutics N.V. to Present at Upcoming","wire":"GlobeNewswire","source":"GlobeNewswire","url":"https://www.globenewswire.com/news-release/2025/11/03/3178840/0/en/Vivoryon-Therapeutics-N-V-to-Present-at-Upcoming-Conferences.html","read_by":"Tavily search (wire domains) + URL date","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"G0PDpBXA562leTZLPGLctar_jiz8Wt6kXpBKTO4FeGdq2YwFKQJ30BpVgbujCtdg0sBJAhTYzFPn0z4uN3dtDQ","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-10-16","event_type":"directors_dealings","title":"F. Weber","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=181999","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"1Wtl4c8WtjDDStiCB3F39KoI9idXRH_vCO_dUPPyz5C6ZWmmNROU6HUkMFh_3r0kdDgajylsNdoCMODIa85hCg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-10-16","event_type":"directors_dealings","title":"J. Neugebauer","category":"directors' and supervisory board transactions","language":"nl","wire":"AFM","source":"AFM register — directors' and supervisory board transactions","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/bestuurders-commissarissen/details?id=182044","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: directors' and supervisory board transactions; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"gp9J0QWL2yi0UFiOhEzGLsu7DqpCnq3Sf9LBz3V9gHJ11XiLSsFmDLI6hnTEZz51_Dw7gQO2cRQ6Iowt1__TCw","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-10-10","event_type":"newswire_release","title":"Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics - Business Wire","wire":"Business Wire","source":"Business Wire","url":"https://www.businesswire.com/news/home/20251009968216/en/Bristol-Myers-Squibb-Strengthens-and-Diversifies-Cell-Therapy-Portfolio-with-Acquisition-of-Orbital-Therapeutics","read_by":"Tavily search (wire domains) + published_date","detail":"matched on distinctive token 'therapeutics'","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"WxxOGIz5EvZtgN5Aq2WNR_udoOdCDMnhIxlEQE8L8gtzoI654mTBQsY5v_rskvGq7iNst-t2tDhw9RIPkT7JBg","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}},{"cmr":"nl-cm-kg/XAMS/NL00150002Q7","date":"2025-10-06","event_type":"ad_hoc","title":"Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million","category":"inside information","wire":"AFM","source":"AFM register — inside information","url":"https://www.afm.nl/en/sector/registers/meldingenregisters/openbaarmaking-voorwetenschap/details?id=C2510-00367","read_by":"AFM notification register (afm.nl, per issuer keyword)","detail":"register: inside information; issuer as registered: Vivoryon Therapeutics N.V.","signature":{"alg":"EdDSA","kid":"allooloo-cmr-2026-10","protected":"eyJhbGciOiJFZERTQSIsImtpZCI6ImFsbG9vbG9vLWNtci0yMDI2LTEwIn0","signature":"L-VIi64GPV6t8QI9Qbxni2sP1WIL_hxbvRJkS2n3dx2WMT9QiDOBWG9q8jhcacT2IL3KRaOYxQL-DM0NoylbDA","jwks":"https://allooloo.ai/.well-known/jwks.json","over":"base64url(protected) + '.' + base64url(canonical JSON of the record without signature: keys sorted, compact)"}}],"events_signed":"allooloo-cmr-2026-10"}